AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10201419 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot the Word Test (STW)
Number of subjects: 25
Study 10201419 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic variables added to NART
Number of subjects: 25
Study 10201419 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic variables added to CCRT
Number of subjects: 25
Study 10201419 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic variables added to STW
Number of subjects: 25
Study 7784025 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot 7.5 mg
Number of subjects: 309
Study 7784025 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot 3.75 mg
Number of subjects: 309
Study 7784025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 7784025 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (both dosages)
Number of subjects: 309
Study 2327885 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-supervised exercise
Number of subjects: 52
Study 2327885 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hospital-supervised bicycling with home walking
Number of subjects: 52
Study 2327885 — intervention group
Group type: COMPARATOR
Intervention: Home exercise with no specific guidance
Number of subjects: 52
Study 2327885 — intervention group
Group type: EXPERIMENTAL
Intervention: Home walking and hospital bicycling
Number of subjects: 52
Study 2327885 — intervention group
Group type: COMPARATOR
Intervention: Completely unsupervised exercise at home
Number of subjects: 52
Study 2327885 — intervention group
Group type: EXPERIMENTAL
Intervention: Different exercise programs
Number of subjects: 52
Study 6159077 — intervention group
Group type: EXPERIMENTAL
Intervention: vinblastine-bleomycin
Number of subjects: 42
Study 6159077 — intervention group
Group type: EXPERIMENTAL
Intervention: doxorubicin-DDP
Number of subjects: 42
Study 31948292 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular revascularization
Number of subjects: 7746
Study 30273493 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (2 × 200 mg/day for 8 weeks)
Number of subjects: 35
Study 30273493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 29461622 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 225
Study 26228543 — intervention group
Group type: COMPARATOR
Intervention: Single vision lenses
Number of subjects: 44
Study 26228543 — intervention group
Group type: COMPARATOR
Intervention: Control lens (AirOptix Aqua)
Number of subjects: 44
Study 26228543 — intervention group
Group type: EXPERIMENTAL
Intervention: Night and Day lens
Number of subjects: 44
Study 26228543 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal lenses
Number of subjects: 44
Study 26228543 — intervention group
Group type: EXPERIMENTAL
Intervention: Proclear Multifocal lenses
Number of subjects: 44
Study 24240611 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical CPR (LUCAS Chest Compression System)
Number of subjects: 2589
Study 24240611 — intervention group
Group type: COMPARATOR
Intervention: Manual CPR (according to guidelines)
Number of subjects: 2589
Study 24240611 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical CPR
Number of subjects: 2589
Study 24240611 — intervention group
Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 2589
Study 22440214 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin/Ezetimibe combination
Number of subjects: 1542
Study 22440214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1542
Study 20578224 — intervention group
Group type: EXPERIMENTAL
Intervention: PEVI plus anticoagulation
Number of subjects: 169
Study 20578224 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulation alone
Number of subjects: 169
Study 18050627 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group (n=30) with manual acupuncture stimulation of Ganshu (BL18), Pishu (BL20), Zusanli (ST 36), once daily for 30 days, in addition to diet-control and medication (Gliguidone 30-60 mg, t.i.d. or insulin).
Number of subjects: 54
Study 18050627 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=24) with diet-control and medication (Gliguidone 30-60 mg, t.i.d. or insulin).
Number of subjects: 54
Study 16045376 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight maintenance diet
Number of subjects: 188
Study 16045376 — intervention group
Group type: COMPARATOR
Intervention: Assessment‐only controls
Number of subjects: 188
Study 12394555 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing-based case management
Number of subjects: 66
Study 12394555 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 66
Study 10615719 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (2‐mg or 8‐mg tablets; maximum daily dose 8 mg)
Number of subjects: 60
Study 10615719 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone (racemic D ‐/+ L‐methadone; maximum daily dose 80 mg)
Number of subjects: 60
Study 8960988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal and oral misoprostol (100 micrograms intravaginally followed by 100 micrograms p.o. every 2 h)
Number of subjects: 224
Study 8960988 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin/PGE2 gel (PGE2 cervical instillation 6 h before continuous oxytocin infusion)
Number of subjects: 224
Study 8960988 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (100 micrograms)
Number of subjects: 224
Study 8960988 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin/PGE2 gel
Number of subjects: 224
Study 1760601 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial resection
Number of subjects: 51
Study 1760601 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 51
Study 6177963 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11
Study 6177963 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 11
Study 31438789 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous trigger finger release combined with finger splint (group II)
Number of subjects: 65
Study 31438789 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous release therapy regimen alone (group I)
Number of subjects: 65
Study 29437032 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision support group
Number of subjects: 46042
Study 29437032 — intervention group
Group type: COMPARATOR
Intervention: No decision support group
Number of subjects: 46042
Study 28779742 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic cloves at 20g.kg‐1 (T3)
Number of subjects: 0
Study 28779742 — intervention group
Group type: COMPARATOR
Intervention: Control group (T1)
Number of subjects: 0
Study 28779742 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic peels and cloves at 0, 10, 20, and 30g.kg‐1
Number of subjects: 0
Study 24464736 — intervention group
Group type: COMPARATOR
Intervention: PIDS 0 ms mode
Number of subjects: 24
Study 24464736 — intervention group
Group type: COMPARATOR
Intervention: PIDS optimized mode
Number of subjects: 24
Study 24464736 — intervention group
Group type: COMPARATOR
Intervention: Control group (PIDS off)
Number of subjects: 24
Study 22913036 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate feedback during testing
Number of subjects: 72
Study 22913036 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 72
Study 22913036 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated feedback
Number of subjects: 72
Study 20935338 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based weight loss program
Number of subjects: 442
Study 20935338 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based weight loss program
Number of subjects: 442
Study 20935338 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 442
Study 17631069 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty or coronary artery bypass graft surgery
Number of subjects: 0
Study 17631069 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM)
Number of subjects: 0
Study 15687128 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/d
Number of subjects: 30
Study 15687128 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 30
Study 11831544 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg for 7 days, followed by 400 mg for 21 days)
Number of subjects: 28
Study 11831544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10086200 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire
Number of subjects: 474
Study 10086200 — intervention group
Group type: COMPARATOR
Intervention: Physician evaluation
Number of subjects: 474
Study 7734740 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified treatment
Number of subjects: 102
Study 7734740 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 102
Study 2073711 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate 2.5 mg/kg
Number of subjects: 16
Study 2073711 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate 5 mg/kg
Number of subjects: 16
Study 2073711 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate 7.5 mg/kg
Number of subjects: 16
Study 2073711 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate 15 mg/kg
Number of subjects: 16
Study 6760657 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir treatment
Number of subjects: 43
Study 31598495 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) 1 mic/kg at induction followed by 0.4 to 0.8 mic/kg/hour during maintenance
Number of subjects: 72
Study 31598495 — intervention group
Group type: COMPARATOR
Intervention: Control group received normal saline instead of DEX
Number of subjects: 72
Study 31598495 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 72
Study 28240760 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal muscle vibration therapy combined with progressive modular rebalancing
Number of subjects: 0
Study 28240760 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 0
Study 28240760 — intervention group
Group type: COMPARATOR
Intervention: Focal muscle vibration therapy alone
Number of subjects: 0
Study 25567476 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous methylnaltrexone bromide 12 mg (MNTX group)
Number of subjects: 137
Study 25567476 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo group)
Number of subjects: 137
Study 24216285 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 800
Study 24216285 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 800
Study 23135087 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% spray
Number of subjects: 2236
Study 23135087 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% spray (monotherapy or add-on therapy)
Number of subjects: 2236
Study 18564044 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 18
Study 18564044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 18564044 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 40 mg
Number of subjects: 18
Study 17513621 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (40 mg)
Number of subjects: 30
Study 17513621 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1000 microg)
Number of subjects: 30
Study 17061994 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal (1 mg/month)
Number of subjects: 92
Study 17061994 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued corticosteroids)
Number of subjects: 92
Study 15261314 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-injection technique (Group 2)
Number of subjects: 60
Study 15261314 — intervention group
Group type: COMPARATOR
Intervention: Single-injection technique (Group 1)
Number of subjects: 60
Study 11192132 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg + metformin
Number of subjects: 328
Study 11192132 — intervention group
Group type: COMPARATOR
Intervention: Placebo + metformin
Number of subjects: 328
Study 11192132 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label pioglitazone + metformin
Number of subjects: 328
Study 11192132 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 328
Study 9359980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg/day)
Number of subjects: 65
Study 9359980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 1489024 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol
Number of subjects: 50
Study 1489024 — intervention group
Group type: COMPARATOR
Intervention: Balanced volatile technique with thiopentone/enflurane
Number of subjects: 50
Study 3937407 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (Mi) 100 mcg, 4 doses/day
Number of subjects: 29
Study 3937407 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 29
Study 31980954 — intervention group
Group type: EXPERIMENTAL
Intervention: PAV
Number of subjects: 18
Study 31980954 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 18
Study 31980954 — intervention group
Group type: COMPARATOR
Intervention: Baseline ventilation
Number of subjects: 18
Study 31714945 — intervention group
Group type: EXPERIMENTAL
Intervention: Route choice model estimated with representative OD pairs
Number of subjects: 9
Study 31714945 — intervention group
Group type: COMPARATOR
Intervention: Route choice model estimated over randomly selected OD pair configurations
Number of subjects: 9
Study 28774880 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m2 intravenously daily for 3 consecutive days on a 28-day cycle
Number of subjects: 113
Study 28774880 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine 75 mg/m2 intravenously/subcutaneously daily for 3 consecutive days on a 28-day cycle
Number of subjects: 113
Study 28774880 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 113
Study 28774880 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine
Number of subjects: 113
Study 25440646 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 30
Study 25440646 — intervention group
Group type: COMPARATOR
Intervention: Control (no RIPC)
Number of subjects: 30
Study 23072448 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (SSC) initiated with father
Number of subjects: 104
Study 23072448 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (SSC) initiated with mother
Number of subjects: 104
Study 23072448 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (SSC)
Number of subjects: 104
Study 21444799 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (20 mg) administered orally 1 h before each treatment session
Number of subjects: 40
Study 21444799 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered orally 1 h before each treatment session
Number of subjects: 40
Study 19103797 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-step essay strategy (analyzing the essay prompt, outlining, writing a response, and reviewing the answer)
Number of subjects: 0
Study 19103797 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what the control intervention was)
Number of subjects: 0
Study 19103797 — intervention group
Group type: COMPARATOR
Intervention: Students without learning disabilities (nominated by teachers as average writers)
Number of subjects: 0
Study 16472043 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling intervention
Number of subjects: 0
Study 16472043 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 15479319 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 43
Study 15479319 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 43
Study 15479319 — intervention group
Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 43
Study 15479319 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib
Number of subjects: 43
Study 11138827 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 65 years
Number of subjects: 29133
Study 11138827 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking years > 40 years
Number of subjects: 29133
Study 11138827 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure > 160 mmHg
Number of subjects: 29133
Study 11138827 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure > 100 mmHg
Number of subjects: 29133
Study 11138827 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum total cholesterol > 6.5 mmol/liter
Number of subjects: 29133
Study 11138827 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol > 1.5 mmol/liter
Number of subjects: 29133
Study 11138827 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy intake (highest quartile)
Number of subjects: 29133
Study 9576141 — intervention group
Group type: EXPERIMENTAL
Intervention: FP 50 microg, twice daily for 8 weeks
Number of subjects: 138
Study 9576141 — intervention group
Group type: EXPERIMENTAL
Intervention: FP 100 microg, twice daily for 8 weeks
Number of subjects: 138
Study 9576141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 9576141 — intervention group
Group type: EXPERIMENTAL
Intervention: FP 200 microg/day (averaged over all visits)
Number of subjects: 138
Study 7831448 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 89
Study 7831448 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 89
Study 3376919 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum (7 sticks for 15 min)
Number of subjects: 12
Study 3376919 — intervention group
Group type: COMPARATOR
Intervention: Cheeseburger (chewed for 15 min)
Number of subjects: 12
Study 30414275 — intervention group
Group type: EXPERIMENTAL
Intervention: Test cream (biomimetic, niacinamide-containing moisturizing cream) applied twice daily for 4 weeks
Number of subjects: 138
Study 30414275 — intervention group
Group type: COMPARATOR
Intervention: No treatment (standard cleanser only)
Number of subjects: 138
Study 29116597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (160 mg subcutaneously 2 weeks prior and 80 mg on the day of vaccination)
Number of subjects: 83
Study 29116597 — intervention group
Group type: COMPARATOR
Intervention: Control (vaccinations alone)
Number of subjects: 83
Study 25724983 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing walking activity
Number of subjects: 45
Study 25724983 — intervention group
Group type: EXPERIMENTAL
Intervention: Social approach for potential interventions
Number of subjects: 45
Study 25724983 — intervention group
Group type: EXPERIMENTAL
Intervention: Spoken content and delivery of interventions
Number of subjects: 45
Study 25724983 — intervention group
Group type: EXPERIMENTAL
Intervention: Local informal settings for interventions
Number of subjects: 45
Study 25724983 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometers for self-monitoring
Number of subjects: 45
Study 23369505 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency random noise stimulation (tRNS) applied during task execution
Number of subjects: 0
Study 23369505 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) applied before task execution
Number of subjects: 0
Study 23369505 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study 21683332 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted Descemet stripping endothelial keratoplasty (FS DSEK)
Number of subjects: 80
Study 21683332 — intervention group
Group type: COMPARATOR
Intervention: Penetrating keratoplasty (PK)
Number of subjects: 80
Study 18301939 — intervention group
Group type: EXPERIMENTAL
Intervention: General health surveillance in infancy
Number of subjects: 0
Study 18301939 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about mother-child relationship
Number of subjects: 0
Study 17062806 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined people and pets (PP) exercising together (PPET) weight loss program
Number of subjects: 92
Study 17062806 — intervention group
Group type: COMPARATOR
Intervention: Overweight or obese people only (PO)
Number of subjects: 92
Study 15615667 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of impulsivity
Number of subjects: 92
Study 15615667 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of impulsive-aggression
Number of subjects: 92
Study 10769438 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (0.5‐1 microgram/day) for 2 years
Number of subjects: 112
Study 10769438 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 112
Study 9126179 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw movement and surface EMG of the masseter and temporal muscles recorded during cycles with an impulse (5 N, 10 ms) applied at 8 different phases of the open-close cycle.
Number of subjects: 0
Study 9126179 — intervention group
Group type: COMPARATOR
Intervention: Jaw movement and surface EMG of the masseter and temporal muscles recorded during cycles without an impulse.
Number of subjects: 0
Study 9126179 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional external force of 20 N applied to the mandible during cycles.
Number of subjects: 0
Study 1440175 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 42
Study 1440175 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 3103169 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g intravenous aspirin
Number of subjects: 6
Study 3103169 — intervention group
Group type: COMPARATOR
Intervention: 1 g oral aspirin
Number of subjects: 6
Study 28873036 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Observation Physical Training (AOPT)
Number of subjects: 24